38 research outputs found
Late-Onset Erythropoietic Porphyria Caused by a Chromosome 18q Deletion in Erythroid Cells
The erythropoietic porphyrias, erythropoietic protoporphyria and congenital erythropoietic porphyria, result from germline mutations in the ferrochelatase gene and uroporphyrinogen III synthase gene, respectively. Both conditions normally present in childhood but rare cases with onset past the age of 40 y have been reported. Here we show that late-onset erythropoietic protoporphyria can be caused by deletion of the ferrochelatase gene in hematopoietic cells with clonal expansion as part of the myelodysplastic process. This is the first direct demonstration of porphyria produced by an acquired molecular defect restricted to one tissue. Some other cases of late-onset erythropoietic porphyria may be explained by a similar mechanism
Exonic deletions as a cause of erythropoietic protoporphyria
Erythropoietic protoporphyria (EPP) is an inherited disorder that results from partial deficiency of ferrochelatase (FECH), the terminal enzyme of haem biosynthesis. Current methods that examine the exons and their flanking regions of the FECH gene fail to identify mutations in about one in seven of families with EPP. The presence in some families of intragenic deletions that are not identifiable by current methods for sequencing the FECH gene may partly explain the low sensitivity of mutation detection in EPP. Here we describe the identification by gene dosage analysis of a deletion of exons 3 and 4 in a family with EPP in whom a mutation had not been found by sequencing-based methods
A homozygous mutation in the ferrochelatase gene underlies erythropoietic protoporphyria associated with palmar keratoderma - reply [Letter]
Diagnostic strategies for autosomal dominant acute porphyrias: retrospective analysis of 467 unrelated patients referred for mutational analysis of the HMBS, CPOX, or PPOX gene
BACKGROUND: Clinically indistinguishable attacks of
acute porphyria occur in acute intermittent porphyria
(AIP), hereditary coproporphyria (HCP), and variegate
porphyria (VP). There are few evidence-based diagnostic
strategies for these disorders.
METHODS: The diagnostic sensitivity of mutation detection
was determined by sequencing and gene-dosage
analysis to search for mutations in 467 sequentially referred,
unrelated patients. The diagnostic accuracy of
plasma fluorescence scanning, fecal porphyrin analysis,
and porphobilinogen deaminase (PBGD) assay was
assessed in mutation-positive patients (AIP, 260 patients;
VP, 152 patients; HCP, 31 patients).
RESULTS: Sensitivities (95% CI) for mutation detection
were as follows: AIP, 98.1% (95.6%–99.2%); HCP,
96.9% (84.3%–99.5%); VP, 100% (95.7%–100%). We
identified 5 large deletions in the HMBS gene (hydroxymethylbilane
synthase) and one in the CPOX
gene (coproporphyrinogen oxidase). The plasma fluorescence
scan was positive more often in VP (99% of
patients) than in AIP (68%) or HCP (29%). The wavelength
of the fluorescence emission peak and the fecal
coproporphyrin isomer ratio had high diagnostic specificity
and sensitivity for differentiating between AIP,
HCP, and VP. DNA analysis followed by PBGD assay
in mutation-negative patients had greater diagnostic
accuracy for AIP than either test alone.
CONCLUSIONS: When PBG excretion is increased, 2 investigations
(plasma fluorescence scanning, the coproporphyrin
isomer ratio) are sufficient, with rare exceptions,
to identify the type of acute porphyria. When the
results of PBG, 5-aminolevulinate, and porphyrin
analyses are within reference intervals and clinical suspicion
that a past illness was caused by an acute porphyria
remains high, mutation analysis of the HMBS
gene followed by PBGD assay is an effective strategy for
diagnosis or exclusion of AIP.
© 2009 American Association for Clinical Chemistr
Genotyping method for methylenetetrahydrofolate reductase (C677T thermolabile variant) using heteroduplex technology [Technical Brief]
The frequency of hemochromatosis-associated alleles is increased in British patients with sporadic porphyria cutanea tarda
The cause of the hepatic siderosis and iron overload that is common in porphyria cutanea tarda (PCT) is uncertain. Heterozygosity for genetic hemochromatosis has been supported by some studies of the association between the HLA-A3 antigen and porphyria cutanea tarda but not by others. The hemochromatosis gene is now believed to be located telomeric to HLA-A3 and close to the DNA microsatellite marker D6S1260. We have used this and other microsatellite markers, which together define an ancestral haplotype that is strongly linked to hemochromatosis, to reinvestigate the relationship between these disorders in 41 British patients with sporadic PCT. Fifteen patients carried the hemochromatosis-associated alleles D6S265-1 and D6S105-8. Four of these were homozygous for the ancestral haplotype D6S265-1: D6S105-8: D6S1260-4. We estimate that approximately 37% of British patients with sporadic PCT carry at least one hemochromatosis gene compared with 10% of the general population
Genotyping method for methylenetetrahydrofolate reductase (C677T thermolabile variant) using heteroduplex technology [Technical Brief]
Gene dosage analysis identifies large deletions of the FECH gene in 10% of families with erythropoietic protoporphyria
Erythropoietic protoporphyria (EPP) is an inherited cutaneous porphyria characterized by partial deficiency of ferrochelatase (FECH), accumulation of protoporphyrin IX in erythrocytes, skin, and liver, and acute photosensitivity. Genetic counseling in EPP requires identification of FECH mutations, but current sequencing-based procedures fail to detect mutations in about one in six families. We have used gene dosage analysis by quantitative PCR to identify large deletions of the FECH gene in 19 (58%) of 33 unrelated UK patients with EPP in whom mutations could not be detected by sequencing. Seven deletions were identified, six of which were previously unreported. Breakpoints were identified for six deletions (c.1–7887–IVS1+2425insTTCA; c.1–9629–IVS1+2437; IVS2-1987–IVS4+352del; c.768–IVS7+244del; IVS7+2784–IVS9+108del; IVS6+2350–TGA+95del). Five breakpoints were in intronic repeat sequences (AluSc, AluSq, AluSx, L1MC4). The remaining deletion (Del Ex3–4) is likely to be a large insertion–deletion. Combining quantitative PCR with routine sequencing increased the sensitivity of mutation detection in 189 unrelated UK patients with EPP from 83% (95% CI: 76–87%) to 93% (CI: 88–96%) (P=0.003). Our findings show that large deletions of the FECH gene are an important cause of EPP. Gene dosage analysis should be incorporated into routine procedures for mutation detection in EPP